Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roberto Lang

Cardiovascular Disease Burr Ridge, IL Medical Doctor

NPI 1205998754 CMS profile 281439

180 Harvester Dr Ste 110, Burr Ridge, IL 60527

Open in the dashboard

General payments

$21,700

160 records reported · program years 2019–2025

Research payments

$26,650

Paid to them · 7 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$274,326 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Roberto Lang of Burr Ridge, IL is reported in the CMS Open Payments database as having received $21,700 across 160 general payments and $26,650 in research payments paid to them. Separately, studies naming them as principal investigator received $274,326 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,171 7
2024 General $1,847 9
2023 General $444 23
2022 General $8,936 26
2022 Research $6,700 1
2021 General $5,412 38
2020 General $406 25
2019 General $3,483 32
2019 Research $19,950 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roberto Lang
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Roberto Lang were reported at $1,171. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Roberto Lang Cardiovascular Disease median Middle half National median
2019 $3,483 $450 $127–$1,392 $163
2020 $406 $242 $77–$751 $114
2021 $5,412 $335 $101–$1,037 $132
2022 $8,936 $395 $121–$1,211 $149
2023 $444 $443 $136–$1,283 $160
2024 $1,847 $450 $136–$1,323 $164
2025 $1,171 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Philips Electronics North America Corporation $17,025 7 payments
  2. Edwards Lifesciences Corporation $1,182 7 payments
  3. Ge Healthcare $1,005 3 payments
  4. Novartis Pharmaceuticals Corporation $591 33 payments
  5. AstraZeneca Pharmaceuticals LP $443 31 payments
  6. Pfizer Inc. $393 18 payments
  7. Janssen Pharmaceuticals, Inc $349 23 payments
  8. Lantheus Medical Imaging, Inc. $157 9 payments
  9. Amgen Inc. $149 10 payments
  10. Abbott Laboratories $138 5 payments
  11. Other $267 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $10,858 3 payments
  2. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $3,000 1 payment
  3. Food and Beverage $2,755 150 payments
  4. Honoraria $1,638 1 payment
  5. Education $1,515 1 payment
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $982 1 payment
  7. Travel and Lodging $952 3 payments
Products named General payments · program years 2019–2025
  1. (1391) CX50 $6,060 1 payment
  2. Other $4,798 2 payments
  3. US Und $3,000 1 payment
  4. (1667) Ultrasound Options and Upgrades $1,638 1 payment
  5. (5044) MCOT $1,515 1 payment
  6. OPTISON $982 1 payment
  7. EVOQUE $585 4 payments
  8. ENTRESTO $493 29 payments
  9. BRILINTA $360 25 payments
  10. XARELTO $349 23 payments
  11. Other $1,608 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $10,500 4 payments
  2. Amgen Inc. $9,450 2 payments
  3. Caption Health, Inc. $6,700 1 payment

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$102,123

Of which drugs: $1,389

Medicare patients

1,439

Average age 72

Services billed

1,867

763 women, 676 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 55%
Arthritis 54%
Ischemic heart disease 49%
Chronic kidney disease 49%
Diabetes 47%
Atrial fibrillation 37%
COPD 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, octafluoropropane microspheres, per ml Q9956 Office 30 30 $958
Injection, perflutren lipid microspheres, per ml Q9957 Office 14 14 $430

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

167 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record